NasdaqCM - Nasdaq Real Time Price USD
Nephros, Inc. (NEPH)
As of October 31 at 4:00 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,770.0000
14,238.0000
9,975.0000
10,217.0000
8,561.0000
Cost of Revenue
5,456.0000
5,833.0000
5,244.0000
4,584.0000
3,648.0000
Gross Profit
8,314.0000
8,405.0000
4,731.0000
5,633.0000
4,913.0000
Operating Expense
9,683.0000
9,998.0000
9,066.0000
8,885.0000
9,417.0000
Operating Income
-1,369.0000
-1,593.0000
-4,335.0000
-3,252.0000
-4,504.0000
Net Non Operating Interest Income Expense
83.0000
62.0000
-6.0000
-31.0000
-99.0000
Other Income Expense
-8.0000
-44.0000
64.0000
499.0000
77.0000
Pretax Income
-1,294.0000
-1,575.0000
-4,277.0000
-2,784.0000
-4,526.0000
Net Income Common Stockholders
-1,294.0000
-1,575.0000
-7,382.0000
-4,107.0000
-4,766.0000
Diluted NI Available to Com Stockholders
-1,294.0000
-1,575.0000
-7,382.0000
-4,107.0000
-4,766.0000
Basic EPS
-0.12
-0.15
-0.70
-0.41
-0.52
Diluted EPS
-0.12
-0.15
-0.70
-0.41
-0.52
Basic Average Shares
10,490.2200
10,386.0180
10,297.1340
10,017.8300
9,078.5490
Diluted Average Shares
10,490.2200
10,386.0180
10,297.1340
10,017.8300
9,078.5490
Total Operating Income as Reported
-1,369.0000
-1,593.0000
-4,335.0000
-3,252.0000
-4,275.0000
Total Expenses
15,139.0000
15,831.0000
14,310.0000
13,469.0000
13,065.0000
Net Income from Continuing & Discontinued Operation
-1,294.0000
-1,575.0000
-7,382.0000
-4,107.0000
-4,766.0000
Normalized Income
-1,294.0000
-1,575.0000
-4,553.0000
-3,506.0000
-4,995.0000
Interest Income
85.0000
64.0000
14.0000
10.0000
11.0000
Interest Expense
2.0000
2.0000
20.0000
41.0000
110.0000
Net Interest Income
83.0000
62.0000
-6.0000
-31.0000
-99.0000
EBIT
-1,292.0000
-1,573.0000
-4,257.0000
-2,743.0000
-4,416.0000
EBITDA
-1,116.0000
-1,359.0000
-3,906.0000
-2,491.0000
-4,208.0000
Reconciled Cost of Revenue
5,453.0000
5,833.0000
5,111.0000
4,524.0000
3,632.0000
Reconciled Depreciation
176.0000
214.0000
351.0000
252.0000
208.0000
Net Income from Continuing Operation Net Minority Interest
-1,294.0000
-1,575.0000
-4,553.0000
-3,024.0000
-4,766.0000
Total Unusual Items Excluding Goodwill
--
--
--
482.0000
229.0000
Total Unusual Items
--
--
--
482.0000
229.0000
Normalized EBITDA
-1,116.0000
-1,359.0000
-3,906.0000
-2,973.0000
-4,437.0000
12/31/2020 - 9/21/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DXR Daxor Corporation
8.66
-1.03%
POCI Precision Optics Corporation, Inc.
3.8978
+2.57%
SMTI Sanara MedTech Inc.
32.96
-0.11%
RVP Retractable Technologies, Inc.
0.7150
-0.93%
AZTA Azenta, Inc.
41.35
+0.62%
STXS Stereotaxis, Inc.
1.9499
-0.52%
MMSI Merit Medical Systems, Inc.
98.89
+0.23%
PLSE Pulse Biosciences, Inc.
14.98
-14.06%
FEMY Femasys Inc.
1.3480
+1.35%
MBOT Microbot Medical Inc.
0.9400
-1.55%